Blog
RSS FeedPosted by Michael Wonder on 30 Jul 2024
HLS announces reimbursement for Vascepa under Alberta's Provincial Drug Plan
29 July 2024 - With the addition of Alberta's public plan, Vascepa will be available to more than 90% of ...
Posted by Michael Wonder on 18 Jul 2024
BC doctor calls on the province to cover obesity medications
17 July 2024 - A petition from Dr. Ali Zentner asking for more PharmaCare coverage has received almost 1,000 signatures. ...
Posted by Michael Wonder on 17 Jul 2024
CSL Behring announces positive reimbursement decision in Canada for Hemgenix (etranacogene dezaparvovec), the first gene therapy for haemophilia B
16 July 2024 - The positive decision from CADTH recognises the importance of this one-time, single dose innovative treatment for ...
Posted by Michael Wonder on 27 Jun 2024
Expanding our scientific advice services for the life sciences sector in Canada
26 June 2024 - Canada’s Drug Agency is launching a new one year learning period in our Scientific Advice program ...
Posted by Michael Wonder on 01 Jun 2024
New analysis examines role of conditional approvals on access to promising oncology therapies
31 May 2024 - Health Canada’s Notice of Compliance with conditions (NOC/c) policy has been effective in providing people in Canada ...
Posted by Michael Wonder on 30 May 2024
Improving our assessments of drugs with companion diagnostic tests
30 May 2024 - As part of our ongoing initiative to improve and modernise our reimbursement review program, Canada’s Drug Agency ...
Posted by Michael Wonder on 28 May 2024
The impact of proposed price regulations on new patented medicine launches in Canada: a retrospective cohort study
27 May 2024 - The Patented Medicine Prices Review Board (PMPRB), the agency that regulates the prices of patented medicines in ...
Posted by Michael Wonder on 25 May 2024
Moving forward on Pharmacare for Canadians
24 May 2024 - Pharmacare legislation includes universal access to contraception and diabetes medications. ...
Posted by Michael Wonder on 24 May 2024
Bausch Health announces additional public drug plan listings for Uceris (budesonide) aerosol foam to treat mild to moderate distal ulcerative colitis in adults
23 May 2024 - Bausch Health today announced additional Canadian public drug plan listings for Uceris (budesonide) aerosol foam to ...
Posted by Michael Wonder on 23 May 2024
PMPRB report examines availability and pricing of new medicines
22 May 2024 - The Patented Medicine Prices Review Board (PMPRB) published the eighth edition of its annual Meds Entry Watch ...
Posted by Michael Wonder on 22 May 2024
The National Advisory Committee on Immunization recommends Beyfortus to protect all infants against RSV
21 May 2024 - The National Advisory Committee on Immunization issued a recommendation for Beyfortus (nirsevimab) to be used for the ...
Posted by Michael Wonder on 10 May 2024
When will Canada have national pharmacare?
22 April 2024 - Canadians support it, public health demands it, now policy makers must deliver it. ...
Posted by Michael Wonder on 02 May 2024
CADTH is now Canada’s Drug Agency
1 May 2024 - As of today, we will adopt Canada’s Drug Agency (CDA-AMC) as our new operating name. ...
Posted by Michael Wonder on 30 Apr 2024
Oh, Canada: US patients don't want your health policies
29 April 2024 - There's never been a worse time to get sick in Canada. Our northern neighbors must wait ...
Posted by Michael Wonder on 19 Apr 2024
National pharmacare will reduce access to new medicines for 27 million privately insured Canadians
18 April 2024 - The federal Liberal-NDP coalition government recently announced it would work with the provinces to fund universal prescription ...